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Abstract: Background: Triple-negative breast cancers (TNBC) are characterized by 
aggressive tumour biology resulting in a poor prognosis. Androgen receptor (AR) is one of 
newly emerging biomarker in TNBC. In recent years, ARs have been demonstrated to play 
an important role in the genesis and in the development of breast cancer, although their 
prognostic role is still debated. In the present study, we explored the correlation of AR 
expression with clinical, pathological and molecular features and its impact on prognosis in 
early TNBC. Patients and Methods: ARs were considered positive in case of tumors with 
>10% nuclear-stained. Survival distribution was estimated by the Kaplan Meier method. 
The univariate and multivariate analyses were performed. The difference among variables 
were calculated by chi-square test. Results: 81 TNBC patients diagnosed between January 
2006 and December 2011 were included in the analysis. Slides were stained 
immunohistochemically for estrogen and progesterone receptors, HER-2, Ki-67, ALDH1, 
e-cadherin and AR. Of the 81 TNBC samples, 18.8% showed positive immunostaining for 
AR, 23.5% and 44.4% of patients were negative for e-cadherin and ALDH1, respectively. 
Positive AR immunostaining was inversely correlated with a higher Ki-67 (p < 0.0001) and 
a lympho-vascular invasion (p = 0.01), but no other variables. Univariate survival analysis 
revealed that AR expression was not associated with disease-free survival (p = 0.72) or 
overall survival (p = 0.93). Conclusions: The expression of AR is associated with some 
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biological features of TNBC, such as Ki-67 and lympho-vascular invasion; nevertheless 
the prognostic significance of AR was not documented in our analysis. However, since 
ARs are expressed in a significant number of TNBC, prospective studies in order to 
determine the biological mechanisms and their potential role as novel treatment target.  
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1. Introduction 
Triple negative breast cancer (TBNC) is a subtype of breast cancer defined by estrogen receptor 
(ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) negativity. 
Therefore it cannot benefit from endocrine therapy and HER-2-target therapy.  
Owing to the aggressive tumor biology and lack of targeted therapy, TNBC is characterized by a 
dismal although heterogeneous outcome. Recently, considerable efforts have been made to sub-classify 
TNBC into different prognostic groups to select patients who are candidates for more or less 
aggressive therapy regimens. Many studies have assessed new biomarkers able to identify patients 
with different prognosis. One of the most extensively investigated but also controversial biomarker is 
the androgen receptor (AR). Androgens are involved in the functions of different female organs, 
including the reproductive tract, bone, kidneys and muscle, acting indirectly as pro-hormones of 
estradiol or directly by binding to the androgen receptor (AR) [1]. The AR is the most prevalent sex 
steroid receptor occurring in up to 90% of breast cancers in early and metastatic setting [2–4] and in a 
lower rate in TNBC (0–53%) [5,6]. Although there is a growing evidence about the role of androgens 
and AR in breast cancer pathogenesis, the role of AR pathway in TNBC is still uncertain; conflicting 
results are reported in preclinical studies and their impact on clinical outcome is still debated [7–9]. In 
cell lines experiments androgens have been shown to have inhibitory and stimulatory effects on TNBC 
cell proliferation [10,11]. Several studies explored the potential significance of AR for therapeutic 
management of both primary and advanced disease, especially in TNBC due to the lack of any other 
targets. In the present study, we assessed ARs expression and their effect on prognosis in TNBC.  
2. Experimental 
Breast cancer patients diagnosed with stage I–III TNBC, undergoing adjuvant chemotherapy at our 
Institution from January 2006 and December 2011, were eligible for this analysis. Patients who 
received preoperative chemotherapy or with stage IV of disease were excluded. We analyzed several 
parameters: clinical (age, performance status, type of surgery, adjuvant chemotherapy), pathological 
(tumor size, grading, necrosis, lymph nodes status, tumor histology, Ki-67, lympho-vascular invasion, 
androgen receptor expression) and molecular (ALDH1 and e-cadherin).  
2.1. Immunohistochemistry 
Tissue samples were fixed in 10% buffered formalin and embedded in paraffin wax for routine 
histological examinations. The slides were stained with hematoxylin and eosin (H & E) with additional 
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immunostaining for ER (clone: SP1, dilution: 1:200; NeoMarkers, Fremont, CA, USA), PR (clone: 
SP2, dilution: 1:250; NeoMarkers), Her2/neu (Herceptest, Dako, Carpinteria, CA, USA), Ki-67 (1:200, 
M7240, Dako), AR (1:60 F39.4.1, BioGenex San Ramon, CA, USA), ALDH1 (Clone 44/ALDH, 
1:200, Transduction Laboratories, Franklin Lakes, NJ, USA) and e-cadherin (clone NCH-38, 1:50 
Dako). ER, PR and AR were considered positive if there were at least 10% positive invasive tumor 
nuclei in the sample. HER-2 status was evaluated by immunohistochemistry (IHC) using a 
semiquantitative score (0–3+). Tumor staining was compared to the staining of normal breast 
epithelium from the same patient as a negative control. For clinical purposes, no staining or weak (1+) 
and incomplete membrans’staining was considered a negative result. Patients with 2+ IHC staining for 
HER2 underwent fluorescence in-situ hybridization to confirm HER2 negativty. Triple-negative status 
(ER negative, PR negative and HER-2 negative) was finally diagnosed and re-reviewed by the single 
study pathologist of our Institution. Carcinoma cells with cytoplasmic staining were considered to be 
ALDH1-positive cells. Any proportion of ALDH1-positive carcinoma cells was considered to 
represent epithelial ALDH1 expression. E-cadherin expression was semi-quantitative analysed 
according to the percentage of cells showing membrane positivity: 0, 0% to 10%; 1+, 10% to 30%;  
2+ 30% to 70%; 3+ > 70%. E-cadherin expression was considered positive when scores were ≥2 and 
negative when scores were ≤1.  
2.2. Statistical Analysis 
Disease-free survival (DFS) was defined as the interval between the date of diagnosis of TNBC to 
the date of relapse or progression of disease, or the date of death from any cause. Overall survival (OS) 
was defined as the interval between the date of diagnosis of TNBC to death or last follow-up visit. 
Patients who were not reported to be dead at the time of the analysis were censored at the date they 
were last known to be alive. Survival distribution was estimated by the Kaplan Meier method. The 
association between categorical variables was estimated by Chisquare test. The Cox multivariate 
proportional hazard regression model was used to evaluate the effects of the prognostic factors on 
survival. Significant differences in probability of surviving between the strata were evaluated by  
log-rank test. Hazard ratios and 95% confidence intervals (CIs) were estimated from regression 
coefficients. A significance level of 0.05 was chosen to assess the statistical significance. Statistical 
analysis was performed with MedCalc package (MedCalc® v9.4.2.0 Software, Ostend, Belgium). 
3. Results 
Eighty one (81) patients were included in the analysis. All patients were female, with a median age 
of 54 years (range 28–79 years). The majority of them (59.4%) had a menopausal status. Sixty-eight 
(83.8%) were treated with quadrantectomy and radiotherapy, 13 (16.2%) with radical mastectomy. 
Almost all patients (97.6%) received systemic adjuvant chemotherapy. Regimens are summarized in 
Table 1. Out of 81 TNBC, 76 (93.8%) were histologically identified as invasive ductal carcinoma. 
Major part of tumours (82.4%) showed an higher Ki-67 expression (>30%). Vascular invasion was 
found in 17 (21%) patients while the presence of necrosis was detected only in 7 cases. The median 
follow-up time was 52.4 months (range = 2.5–95 months). The median DFS was 44.8 months (range 
2.5–95 months). Fifteen patients (18.8%) showed positive immunostaining for AR while 55.6%, and 
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76.5% were positive for ALDH1 and e-cadherin, respectively. Characteristics of 81 TNBC examined 
in the study are summarized in Table 1. Analysis of the relationship between AR immunostaining and 
clinico-pathological parameters revealed that positive immunostaining was inversely correlated with 
higher Ki-67 (p < 0.0001) and lympho-vascular invasion (p = 0.01). No significant difference between 
the groups with and without positive AR immunostaining in age at diagnosis, menopausal status, size 
of tumor, histological features, ALDH1 and e-cadherin immunostaining was identified (Table 1).  
Table 1. Baseline characteristics of the 81 patients with early TNBC. 
Characteristics 
Total  
No. of Pt (%) 
AR negative 
No. of Pt (%) 
AR positive 
No. of Pt (%) 
p-value 
Age 
≤50 years  
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Table 1. Cont. 
Characteristics 
Total  
No. of Pt (%) 
AR negative 
No. of Pt (%) 
AR positive 

































































































Abbreviations: AR = androgen receptor; CK 5/6 = cytokeratins 5/6; ALDH1 = aldehyde dehydrogenase 1. 
Univariate survival analysis revealed that positive immunostaining for AR was not associated with 
DFS (p = 0.72) and OS (p = 0.93) (Tables 2 and 3). No clinical or biological variables were significantly 
related to DFS while the only factor which is significantly related to a worsened OS was the presence 
of necrosis (p = 0.002). Multivariate analysis confirmed that the presence of necrosis was the 
significant independent prognostic variable influencing OS (p = 0.007; HR = 6.78, 95% CI 1.67–27.5).  
Table 2. Univariate Cox regression analysis of factors associated with disease-free survival 
in early triple negative breast cancer. 
Parameters 
Univariate analysis 
HR 95% CI p-value 
Age, years 















Tumour size (at diagnosis) 







Lymph node status (pN) 
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Table 2. Cont. 
Parameters 
Univariate analysis 
HR 95% CI p-value 
Ki-67 































































Table 3. Univariate and multivariate Cox regression analysis of factors associated with 
overall-survival in early triple negative breast cancer. 
Parameters 
Univariate analysis Multivariate analysis 
HR 95% CI p-value HR 95% CI p-value 
Age, years 
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4. Discussion 
TNBC represents a group of breast cancer with poor prognosis, owing to aggressive tumor biology 
and lack of targeted therapy-like HER2 blocking agents or hormonal therapy [12]. However, several 
reports suggested that TNBC could represent a heterogeneous group comprising different subtypes 
with different clinical outcomes. Many published studies have attempted to identify new biomarkers to 
combine with those available in clinical practice to sub-classify TNBC into different prognostic groups 
and to select patients who are candidates for more aggressive therapy regimens. 
There is a growing body of evidence that androgen signaling pathway plays a critical role in normal 
and malignant breast tissue [13]. The AR is the most prevalent sex steroid receptor occurring in up to 
90% of all breast cancers (in situ and invasive disease including early and metastatic setting) [2–4] and 
in a lower rate in TNBC (0%–53%) [5,6]. The overall frequency of AR in carcinoma cells varies 
considerably among the studies, even if a 10% cut-off point has been selected to define AR positivity. 
This heterogeneity may be largely due to the methodological differences in AR analysis. Further, 
several analyses based on unselected breast cancer cohorts showed that AR expression is related with 
ERα and PgR immunostaining as well as a marker of low grade differentiated disease [2–4,14–16]. 
Although several pre-clinical and genomic studies defined AR as a potential tumor suppressor of  
ERα-positive breast cancer with antiproliferative effect due to the cross talk between these steroid 
receptor signaling pathways [4], studies investigating the biological role and the clinic-pathological 
features of AR expression in TNBC reported conflicting results. Furthermore, Farmer et al. [17] 
proposed a new classification of breast cancer subtypes based on ERα and AR status: luminal disease 
positive for both receptors (ERα+/AR+), basal disease negative for both receptors (ERα−/AR−) and 
molecular apocrine disease with ERα negative and AR positive staining, showing similar characteristics 
to those of the normal apocrine glands. Following analyses showed that in molecular apocrine cancers 
there is a cross talk between AR and HER2 pathway with a trend of poor outcome [18–20]. While ARs 
showed inhibitory activity on ERα pathway with antiproliferative effect in ERα-positive breast tumor 
cells and ARs levels could be predictive of the outcome in luminal subtypes [21,22], their role is still 
unclear in TNBC.  
Birell et al.’s [10] in vitro analyses indicated a growth inhibition effect of AR pathway in cell lines 
expressing ER and PR, while proliferative effects were found in ER and PR negative cell lines. The 
authors suggested that androgen action may be mediated, beyond by binding of androgen to the 
androgen receptors, by metabolites of dihydrotestosterone (DHT), also due to its estrogenic activity. 
Garay et al. [11] reported that the activation of the mitogen activated protein kinase (MAPK) pathway 
by either EGFR or AR leads to cellular proliferation, but they also found that hyperactivation of the 
MAPK pathway from both AR and EGFR signaling resulted in a growth-inhibitory response. 
Furthermore some results of in vitro investigations suggested that AR may displace ER and PR as a 
driver of tumor proliferation and growth in TNBC cell lines [1,13,23–28]. Several published studies 
have analyzed the relationship between AR immunostaining and clinico-pathological parameters. The 
expression of AR was inversely correlated with higher clinical stage, higher mitotic score and higher 
histological grade suggesting AR positive TNBC could be less aggressive tumors [7,8,24–31]. On the 
contrary McGhan et al. [32] reported in their study a higher propensity for lymph node (LN) 
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metastases, more advanced disease and poorer recurrence free survival in AR positive TNBC. In our 
study a positive immunostaining for AR was detected in 18.8% of TNBC.  
AR positivity was inversely correlated with higher Ki-67 (p < 0.0001) and lympho-vascular 
invasion (p = 0.01), while we did not find any relationship with age, menopausal status, size of tumor, 
histological features, ALDH1 and e-cadherin immunostaining (Table 1). Similar findings were 
reported by Mrklic et al. [33]. They observed an inversely correlation between proliferative index 
measured by Ki 67 antigen and AR status (33.7% vs. 7.2%, p = 0.014), suggesting that androgens 
might have an antiproliferative effect. AR immunostaining was also inversely correlated with higher 
clinical stage (p = 0.0259, higher mitotic score (p = 0.003) and higher histological grade (p = 0.038), 
but no significant difference between two groups in vascular invasion and other parameters.  
Sutton et al. [34] revealed that among the AR-positive TNBC, distant metastases are significantly 
associated with lower expression of AR compared with cases with only locoregional disease, and that 
AR expression negatively correlates with Ki-67 expression. Other studies observed an inverse 
correlation between positive AR immunostaining and high Ki-67 status [7,31,35–37]. 
Several studies in recent years highlighted the role of AR as independent prognostic factor for 
luminal breast cancer, confirming their tumor suppressive effect on ERα pathway [4]. On the other 
hand the impact on outcome of AR expression in triple-negative tumors is still unclear.  
Some studies indicated an improved survival [5,6,32,33], while others worse survival [30] or no 
significant effects [13,18,25–27]. Our study did not show any significant correlation between AR 
status and survival. However, there are some limitations to this study. This is a retrospective analysis 
of data collected in a single institution, on a total number of patients included relatively small and so it 
could be underpowered to make definitive conclusions. 
The relevant discordance about the prognostic role of AR expression may be due to the complexity 
of this pathway. McNamara et al. analyzed [35] the AR status in combination with androgen synthesizing 
enzyme 5α-reductase type 1 (5αR1) and 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5). The 
presence of androgen synthesizing pathway in addition to AR expression in tumor cells (AR+/enzyme+) 
could confer a better clinical outcome through suppression of cell proliferation. Therefore, if we want 
to know the impact of AR expression on prognosis, we need to asses not only the receptor expression 
but also its ligand. Only in presence of a double positivity we could observe a better outcome.  
To date the AR is largely explored as potential therapeutic target, and androgen treatment showed 
some therapeutic benefit in addition to chemotherapy or Tamoxifen in several randomized  
trials [4,38–43]. Other interesting evidence are emerging particularly from androgen hormones 
treatment that may represent a new relevant therapeutic approach for TNBC expressing AR positivity. 
Promising results were obtained by Gucalp et al. [44] in a Phase II trial that showed clinical benefit 
rate of 19% for 6 months in 424 patients with ER/PgR-negative BC underwent bicalutamide 150 mg 
daily with minimal toxicity. These results could suggest that in some circumstances androgens may 
drive tumour proliferation.  
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5. Conclusions  
In conclusion, our study examined the relationship between AR expression and clinical and 
prognostic outcomes in an italian cohort of 81 patients with early TNBC. Univariate analysis revealed 
that AR positivity was inversely correlated with higher Ki-67 (p < 0.0001) and lympho-vascular 
invasion (p = 0.01), although in multivariate analysis this effect was not significant. These findings 
were in line with some of previously published studies. No significant correlation between AR status 
and survival was found. This data is of importance to a growing body of evidence documenting the 
association between AR expression and biological factors in TNBC. However, the role of AR pathway 
in TNBC is still uncertain; conflicting results are reported in preclinical studies and their impact on 
clinical outcome is still debated. Further prospective studies are needed to determine the pathogenetic 
mechanism underlying androgen and their receptors in TNBC to adequately assess the potential role of 
AR pathway as druggable target.  
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